Skip to content
24/7 Wall Street Logo
  • Investing
  • Personal Finance
  • Technology
  • Economy and Geopolitics
    • Economy
    • Politics
    • Crime
    • Infrastructure
    • Military

    Trending Articles

    One Form Can Erase Your IRMAA Surcharge After a Retirement, Divorce, or a Spouse’s Death — You Have 60 Days
    14 minutes ago

    One Form Can Erase Your IRMAA Surcharge After a Retirement, Divorce, or a Spouse’s Death — You Have 60 Days

    Google vs Apple: Which of the 2 Biggest AI Stocks Is the Better Buy Right Now?
    8 hours ago

    Google vs Apple: Which of the 2 Biggest AI Stocks Is the Better Buy Right Now?

  • AI Portfolio
AI Investor Podcast
  • Investing
  • Personal Finance
  • Technology
  • Economy and Geopolitics
    • Economy
    • Politics
    • Crime
    • Infrastructure
    • Military
  • AI Portfolio
S&P 500
7,588.60
+0.51%
Dow Jones
52,758.90
+0.47%
Nasdaq 100
29,885.70
+0.46%
Russell 2000
2,982.51
-0.27%
FTSE 100
10,543.60
+0.61%
Nikkei 225
69,317.20
+0.42%

Investing

CRIS logo Curis : CRIS

CRIS

Stock Data

$4.96

Change up

$0.00 (0.00%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.

All Curis Articles

3 Articles

Top Analyst Upgrades and Downgrades: AMD, Cisco, eHealth, iHeart Media, Intel, Playtika, ViacomCBS, Williams-Sonoma and More
Lee Jackson | Mar 25, 2021 at 8:48 AM EDT

Top Analyst Upgrades and Downgrades: AMD, Cisco, eHealth, iHeart Media, Intel, Playtika, ViacomCBS, Williams-Sonoma and More

Thursday's top analyst upgrades and downgrades included AllianceBernstein, AMD, Cisco, eHealth, iHeart Media, Intel, Playtika, ViacomCBS and Williams-Sonoma.

The Hits Keep Coming With Curis’s Secondary Offering
Chris Lange | Dec 9, 2020 at 9:53 AM EST

The Hits Keep Coming With Curis’s Secondary Offering

Curis shares are on the run again. This time it’s due to a secondary offering.

This Curis Cancer Study Is a Big Hit
Chris Lange | Dec 8, 2020 at 9:56 AM EST

This Curis Cancer Study Is a Big Hit

Curis has announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.

More Content
One Form Can Erase Your IRMAA Surcharge After a Retirement, Divorce, or a Spouse’s Death — You Have 60 Days
Drew Wood • Jul 12, 2026

One Form Can Erase Your IRMAA Surcharge After a Retirement, Divorce, or a Spouse’s Death — You Have 60 Days

Google vs Apple: Which of the 2 Biggest AI Stocks Is the Better Buy Right Now?
Gerelyn Terzo • Jul 11, 2026

Google vs Apple: Which of the 2 Biggest AI Stocks Is the Better Buy Right Now?

The 20% Tax Credit Developers Use to Flip Historic Buildings and How You Can Claim It
Michael Williams • Jul 11, 2026

The 20% Tax Credit Developers Use to Flip Historic Buildings and How You Can Claim It

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

One Form Can Erase Your IRMAA Surcharge After a Retirement, Divorce, or a Spouse's Death — You Have 60 Days
Drew Wood | 14 minutes ago

One Form Can Erase Your IRMAA Surcharge After a Retirement, Divorce, or a Spouse's Death — You Have 60 Days

The 20% Tax Credit Developers Use to Flip Historic Buildings and How You Can Claim It
Michael Williams | 9 hours ago

The 20% Tax Credit Developers Use to Flip Historic Buildings and How You Can Claim It

24/7 Wall St. logo
  • Home
  • About Us
  • Contact Us
  • Financial Tools
  • Disclaimer and Terms of Use
  • Privacy Policy
  • CCPA Privacy Policy
  • Advertise
© 2026 24/7 Wall St.